NEW DATES:

October 14 - 15, 2020

Virtual Event

Agenda

Wednesday October 14, 2020

(Eastern Time)

11:30 - 11:55 AM

 

Visit Exhibits

11:55 - 12:05 PM

 

Introduction
Jacob M. Rowe, MD, Co-Chairman

 

Session 1:  Advances in Myelodysplasia
Moderators:
Rafael Bejar, MD, PhD
Aziz Nazha, MD

12:05 - 12:20

 

How important is genetic predisposition in myelodysplasia?
Akiko Shimamura, MD, PhD

12:20 - 12:30

 

Discussion

12:30 - 12:45

 

How do molecular features guide therapy in myelodysplasia?
Hetty E. Carraway, MD

12:45 - 12:55

 

Discussion

12:55 - 1:10

 

Novel therapeutic strategies in chronic myelomonocytic leukemia
Mrinal S. Patnaik, MBBS

1:10 - 1:20

 

Discussion

1:20 - 1:35

 

Is there a best therapy after failure of hypomethylating agents for MDS?
Amer Zeidan, MBBS

1:35 - 1:45

 

Discussion

1:45 - 2:05

 

Visit Exhibits

 

Session 2:  Novel Strategies in ALL
Moderators:
Wendy Stock, MD
Mignon Loh, MD

2:05 - 2:20

 

CAR-T in adult ALL:  When and for whom?
Noelle V. Frey, MD, MSCE

2:20 - 2:30

 

Discussion

2:30 - 2:45

 

How to manage an older adult with Ph-negative ALL
Jae H. Park, MD

2:45 - 2:55

 

Discussion

2:55 - 3:10

 

Are we making any progress in T-cell ALL?
Adolfo Ferrando, MD, PhD

3:10 - 3:20

 

Discussion

3:20 - 3:35

 

Have any treatment strategies in Ph-like ALL been shown to be effective?
Anjali Advani, MD

3:35 - 3:45

 

Discussion

3:45

 

Visit Exhibits

 

Thursday October 15, 2020

(Eastern Time)

10:00 - 10:10 AM

 

Introduction
Jacob M. Rowe, MD, Co-Chairman

 

Session 1: Basic Biology
Moderators:
Ross Levine, MD
Marshall A. Lichtman, MD

10:10 - 10:25

 

What factors contribute to long-term survival of hematopoietic stem cells?
John E. Dick, PhD, FRS

10:25 - 10:35

 

Discussion

10:35 - 10:50

 

What are the most important mechanisms for drug-resistance in AML?
Marina Konopleva, MD, PhD

10:50 - 11:00

 

Discussion

11:00 - 11:15

 

What are the molecular mechanisms driving the switch from MPNs to leukemia?
Ronald Hoffman, MD

11:15 - 11:25

 

Discussion

11:25 - 11:45

 

Visit Exhibits

 

Session 2: Therapy of Induction, Post-remission and Relapse
Moderators:
Richard Stone, MD
Elihu H. Estey, MD

11:45 - 12:00 PM

 

Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?
Mark Levis, MD, PhD

12:00 - 12:10

 

Discussion

12:10 - 12:25

 

Can one overcome p53 mutations in AML?
David A. Sallman, MD

12:25 - 12:35

 

Discussion

12:35 - 12:50

 

Is there a role for checkpoint inhibitors in AML?
Naval G. Daver, MD

12:50 - 1:00

 

Discussion

1:00 - 1:15

 

Which novel agents will have a clinically meaningful impact in AMLat diagnosis?
Alexander E. Perl, MD, MS

1:15 - 1:25

 

Discussion

1:25 - 1:40

 

Why is there no standard of care for relapsed AML?
Ehab L. Atallah, MD

1:40 - 1:50

 

Discussion

1:50 - 2:10

 

Visit Exhibits

 

Session 3: Bone Marrow Transplantation
Moderators:
Armand Keating, MD

Nelson Chao, MD, MBA

2:10 - 2:25

 

The ever-increasing upper age for transplant:  Is this evidence-based?
Daniel J. Weisdorf, MD

2:25 - 2:35

 

Discussion

2:35 - 2:50

 

Are we making any progress in the management of a patient with chronic GvHD at 12 months?
Mary E. Flowers, MD

2:50 - 3:00

 

Discussion

3:00 - 3:15

 

How to overcome graft failure in haploidentical transplantation?
Xiao-Jun Huang, MD

3:15 - 3:25

 

Discussion

3:25 - 3:40

 

Is there a role for HMAs as post-transplant maintenance?
Frederick R. Appelbaum, MD

3:40 - 3:50

 

Discussion

3:50 - 4:10

 

Visit Exhibits

 

Session 4: Supportive Care and Perspective
Moderators:
Beverly S. Mitchell, MD
Kenneth Kaushansky, MD

4:10 - 4:25

 

Why are there controversies in the recent WHO classification of AML?
Robert P. Hasserjian, MD

4:25 - 4:35

 

Discussion

 

Ernest Beutler Memorial Lecture

4:35 - 4:45

 

Introduction of Connie Eaves
Frederick R. Appelbaum, MD

4:45 - 5:20

 

Stem cells and leukemogenesis
Connie J. Eaves, PhD, FRS(C)

5:20 - 5:30

 

Discussion

5:30 - 5:40

 

Concluding Remarks and Close
Martin S. Tallman, MD, Co-Chairman